


## A Dermocosmetic Significantly Reduces the Frequency and Intensity of Facial Skin Intolerability and Sensitivity in Subjects with Skin Intolerant to Skin Care Products and Sensitive Skin [Corrigendum]

Kerob D, Czermanska A, Karamon EM, et al. *Clin Cosmet Invest Dermatol*. 2023;16:1787–1794.

The authors have advised [Figure 5b](#) on page 1792 is incorrect. Due to an error that occurred inadvertently at the time of figure assembly, figure part b was duplicated from part a. The correct [Figure 5](#) is shown below.



**Figure 5** Biomarkers at Day 0 and Day 14. (a) Interleukin 1 $\alpha$ . (b) Interleukin-1-receptor antagonist. (c) Prostaglandin E2. Differences from Day 0 were statistically significant (\* $p < 0.0001$ ) for all 3 biomarkers after 14 days of daily use.

The authors apologize for this error and advise it does not affect the results of the paper.

Clinical, Cosmetic and Investigational Dermatology

Dovepress

### Publish your work in this journal

Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access, online journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. This journal is indexed on CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal>